CYC116
| Code | Size | Price |
|---|
| SYN-1034-M100 | 100 mg | Enquire |
Quantity:
| SYN-1034-M001 | 1 mg | £80.00 |
Quantity:
| SYN-1034-M005 | 5 mg | £115.00 |
Quantity:
| SYN-1034-M010 | 10 mg | £151.00 |
Quantity:
| SYN-1034-M050 | 50 mg | £420.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
CYC-116
Appearance:
Solid.
CAS:
693228-63-6
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,22,23)
InChiKey:
GPSZYOIFQZPWEJ-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 693228-63-6. Formula: C18H20N6OS. MW: 368.5. CYC116 is an orally active small molecule multi-kinase inhibitor with anti-neoplastic activity. CYC116 inhibits Aurora kinases A/B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis.
Molecular Formula:
C18H20N6OS
Molecular Weight:
368.5
Package Type:
Plastic Vial
Product Description:
CYC116 is an orally active small molecule multi-kinase inhibitor with anti-neoplastic activity. CYC116 inhibits Aurora kinases A/B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Discovery and development of aurora kinase inhibitors as anticancer agents: J.R. Pollard & M.J. Mortimore; J. Med. Chem. 52, 2629 (2009) | Selectivity data: assessment, predictions, concordance, and implications: C. Gao, et al.; J. Med. Chem. 56, 6991 (2013)
Related Products
| Product Name | Product Code | Supplier | Tripolin A | AG-CR1-3520 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A-443654 | AG-CR1-3663 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 7BIO | AG-MR-C0020 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tozasertib | SYN-1092 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||